Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 4
2008 3
2009 4
2010 7
2011 6
2012 4
2013 2
2014 4
2015 4
2016 10
2017 11
2018 12
2019 12
2020 6
2021 19
2022 14
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

110 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Clinical Trial.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280658 Clinical Trial.
Emerging Role of YAP and the Hippo Pathway in Prostate Cancer.
Koinis F, Chantzara E, Samarinas M, Xagara A, Kratiras Z, Leontopoulou V, Kotsakis A. Koinis F, et al. Among authors: kotsakis a. Biomedicines. 2022 Nov 7;10(11):2834. doi: 10.3390/biomedicines10112834. Biomedicines. 2022. PMID: 36359354 Free PMC article. Review.
Cancer therapy and cardiovascular risk: focus on bevacizumab.
Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Economopoulou P, et al. Among authors: kotsakis a. Cancer Manag Res. 2015 Jun 3;7:133-43. doi: 10.2147/CMAR.S77400. eCollection 2015. Cancer Manag Res. 2015. PMID: 26082660 Free PMC article. Review.
Classifying circulating tumor cells to monitor cancer progression.
Economopoulou P, Georgoulias V, Kotsakis A. Economopoulou P, et al. Among authors: kotsakis a. Expert Rev Mol Diagn. 2017 Feb;17(2):153-165. doi: 10.1080/14737159.2017.1275572. Epub 2016 Dec 29. Expert Rev Mol Diagn. 2017. PMID: 28032524 Review.
New prophylaxis strategies to reduce the risk of thromboembolism in cancer.
Papadopoulos V, Tsapakidis K, Markou A, Kokkalis A, Aidarinis C, Kotsakis A. Papadopoulos V, et al. Among authors: kotsakis a. Expert Rev Anticancer Ther. 2021 Oct;21(10):1135-1144. doi: 10.1080/14737140.2021.1941889. Epub 2021 Jun 21. Expert Rev Anticancer Ther. 2021. PMID: 34139938 Review.
110 results